Claims
- 1. A compound selected from the group consisting of:
- 3-�2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz �e!isoindol-1-yl)ethyl!-1-methyl-7-methoxyquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-1-(2-methoxyethyl)-6,7-dimethoxyquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7,8-methylenedioxyquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-6,7-methylenedioxyquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-6,7-dimethoxyquinazoline-4(3H)-one;
- 3-�2-((3aR,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7,8-dimethoxyquinazoline-4(3H)-one;
- 3-�2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7,8-dimethylpyrido�3,2-d!pyrimidine-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)-cis-9-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)butyl!-6,7-dimethoxyquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7-carbomethoxyquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7-carboisopropoxyquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7-carbopropoxyquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR ,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7-nitroquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7-methoxy-8-methyl-quinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7-ethoxy-8-methyl-quinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7,8-dimethylquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-7,8-dimethoxyquinazoline-2,4(1H,3H)-dione;
- 3-�2-((3aR,9bR)cis-6-ethoxy-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-6,7-dimethoxyquinazoline-2,4(1H,3H)-dione; and
- 3-�2-((3aR,9bR)cis-6-Ethyl-2,3,3a,4,5,9b-hexahydro-�1H!-benz�e!isoindol-1-yl)ethyl!-6,7-dimethoxyquinazoline-2,4(1H,3H)-dione;
- or a pharmaceutically acceptable salt thereof.
- 2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.
- 3. A method of antagonizing .alpha.-1 receptors in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of claim 1.
- 4. A method of treating benign prostatic hyperplasia (BPH) in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of claim 1.
- 5. A method of treating benign prostatic hyperplasia (BPH) in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of claim 1 in combination with a 5-.alpha. reductase inhibitor.
- 6. The method of claim 5 wherein said 5-.alpha. reductase inhibitor is finasteride.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application Ser. No. 08/379,823 filed Jan. 27, 1995 now U.S. Pat. No. 5,521,181.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5158953 |
Chern et al. |
Oct 1992 |
|
5420128 |
Kiyokawa et al. |
May 1995 |
|
5521181 |
Meyer et al. |
May 1996 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0095666 |
Dec 1983 |
EPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
379823 |
Jan 1995 |
|